Related Experiment Video
Updated: Apr 30, 2026
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
A mouse bleeding model to study oral anticoagulants
Dougald M Monroe1, Maureane Hoffman1
1University of North Carolina Division of Hematology/Oncology, Chapel Hill, NC, USA; Duke University Department of Pathology, Durham, NC, USA.
Abstract:
New oral anticoagulants to reduce the incidence of thrombosis have recently become available. When compared to the existing therapy, warfarin, these novel agents have similar efficacy with a reduced risk of spontaneous bleeding. However, these novel agents have been associated with significant, even fatal, bleeding following trauma. Reversal agents are being developed that bind and neutralize these oral anticoagulants. However, these are not yet available. Another strategy is to increase thrombin generation by administration of "bypassing" agents such as prothrombin complex concentrates or factor VIIa. Several animal models have been used to model the hemostatic defect induced by the thrombin inhibitor dabigatran. A rat tail injury model, a rabbit cuticle bleeding model, and a rabbit kidney laceration model have all been reported to show increased bleeding, but with supratherapeutic doses of dabigatran. A mouse tail transection model has been reported to reflect increased bleeding at peak therapeutic dabigatran levels. We found that the Whinna saphenous vein hemostasis model reliably reflects a hemostatic defect at therapeutic levels of dabigatran. This model can potentially reflect the effects of reversal or bypassing agents.
Insights
New oral anticoagulants offer effective thrombosis prevention but pose bleeding risks post-trauma. A novel saphenous vein model accurately reflects bleeding defects from dabigatran at therapeutic levels.
Area of Science:
- Pharmacology
- Hematology
- Medical Devices
Background:
- New oral anticoagulants (NOACs) provide alternatives to warfarin for thrombosis prevention.
- While NOACs demonstrate comparable efficacy and reduced spontaneous bleeding, they present significant bleeding risks after trauma.
- Current reversal agents for NOACs are unavailable, necessitating alternative management strategies.
Purpose of the Study:
- To evaluate the efficacy of a novel hemostasis model in assessing bleeding complications associated with NOACs.
- To establish a reliable animal model for studying the effects of dabigatran on hemostasis at therapeutic levels.
- To provide a platform for testing potential reversal or bypassing agents for NOAC-induced bleeding.
Main Methods:
- Utilized the Whinna saphenous vein hemostasis model.
- Administered dabigatran, a direct thrombin inhibitor, to induce a hemostatic defect.
- Assessed bleeding severity at peak therapeutic dabigatran levels.
Main Results:
- The Whinna saphenous vein model demonstrated a reliable reflection of hemostatic defects.
- Increased bleeding was observed at therapeutic dabigatran levels within this model.
- Previous models often required supratherapeutic doses to show bleeding effects.
Conclusions:
- The Whinna saphenous vein hemostasis model is a viable tool for studying NOAC-induced bleeding.
- This model can potentially evaluate the efficacy of bypassing agents in managing dabigatran-related bleeding.
- Further research can utilize this model to develop effective interventions for managing bleeding complications associated with novel oral anticoagulants.
